A drug already FDA-approved for treating obesity has demonstrated efficacy in a lab setting as a possible treatment for opioid dependence. The research, published in the journal ACS Chemical Neuroscience, involved scientists administering the weight-loss drug lorcaserin to rats who had been self-administering oxycodone. Unlike existing treatments which aim to help people quit by blocking the receptors that opioids bind to, lorcaserin (the scientists hypothesize) may be able to rein in cravings before they start.